TANG CAPITAL MANAGEMENT LLC
Q2 2023 Form 13-F
SAN DIEGO, CALIFORNIA
CIK 0001232621
· Institutional investment manager
Consolidated report · includes
1 manager
since Q2 2013
$679.3M Reported Value Total
Reported value
$679.3M
Quarter over quarter
+4.7%
Holdings
99
Top-10 concentration
38.7%
Filing Structure
Reports holdings for
- TANG KEVIN C · File #028-14818 · since Q2 2013
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Kevin Tang
Manager
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $679.3M |
| Positions | 99 |
| Change in reported value | +1.2% |
| New positions | 22 |
| Exited positions | 26 |
| Position turnover | 38.4% |
| Top-10 concentration | 38.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
40 | $2.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
51 | $2.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
75 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
194 | $2.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
200 | $2.0B |
|
Q1 2025 13F
Filed May 15, 2025
|
202 | $1.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
183 | $1.5B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
154 | $1.4B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
127 | $981.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
99 | $960.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
123 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
106 | $708.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
99 | $679.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
103 | $671.1M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
89 | $688.3M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
95 | $815.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
67 | $659.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
51 | $499.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
29 | $497.2M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
20 | $481.7M |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ANAB ANAPTYSBIO INC | $39.7M | 5.84% |
| 2 | TARS TARSUS PHARMACEUTICALS INC | $32.1M | 4.73% |
| 3 | MIRM MIRUM PHARMACEUTICALS INC | $29.4M | 4.33% |
| 4 | IMGN IMMUNOGEN INC | $24.5M | 3.61% |
| 5 | IMCR IMMUNOCORE HLDGS PLC | $24.3M | 3.58% |
| 6 | BLUE BLUEBIRD BIO INC | $24.3M | 3.58% |
| 7 | KALV KALVISTA PHARMACEUTICALS INC | $23.9M | 3.51% |
| 8 | AXSM AXSOME THERAPEUTICS INC | $23.0M | 3.39% |
| 9 | EOLS EVOLUS INC | $22.5M | 3.32% |
| 10 | ITCI INTRA-CELLULAR THERAPIES INC | $19.0M | 2.8% |
| 11 | NYCBXXXX NEW YORK CMNTY BANCORP INC | $18.1M | 2.66% |
| 12 | BCRX BIOCRYST PHARMACEUTICALS INC | $17.2M | 2.54% |
| 13 | VRDN VIRIDIAN THERAPEUTICS INC | $16.5M | 2.43% |
| 14 | ONC BEIGENE LTD | $15.2M | 2.23% |
| 15 | PCVX VAXCYTE INC | $15.0M | 2.21% |
| 16 | LLY LILLY ELI & CO | $14.1M | 2.07% |
| 17 | IFRX INFLARX NV | $12.9M | 1.9% |
| 18 | AZN ASTRAZENECA PLC | $12.2M | 1.79% |
| 19 | CTMX CYTOMX THERAPEUTICS INC | $11.4M | 1.67% |
| 20 | AVIR ATEA PHARMACEUTICALS INC | $11.3M | 1.67% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.